CSIMarket
 
Traws Pharma inc   (NASDAQ: TRAW)
 

Traws Pharma Inc's Suppliers Performance

TRAW's Supply Chain




 
TRAW Costs vs Sales of Suppliers Growth

More on TRAW Suppliers






Traws Pharma Inc's Comment on Supply Chain


The first-in-man clinical study of tivoxavir marboxil was conducted from May to September 2023 in Russia. The study was sponsored by Pharmasyntez, JSC. The company holds the rights to use the data from this study outside of Russia and the Eurasian Economic Community countries. Pharmasyntez, JSC is also listed as a supplier in company filings.

Traws Pharma Inc's Comment on Supply Chain


The first-in-man clinical study of tivoxavir marboxil was conducted from May to September 2023 in Russia. The study was sponsored by Pharmasyntez, JSC. The company holds the rights to use the data from this study outside of Russia and the Eurasian Economic Community countries. Pharmasyntez, JSC is also listed as a supplier in company filings.







TRAW's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Traws Pharma inc 7.99 2.90 -16.74 17
SUBTOTAL 0.00 0.00 0.00 -


Sources: Traws Pharma inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Traws Pharma inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.